Damora Therapeutics, Inc. (DMRA)
Nasdaq: DMRA · Pharmaceutical Preparations · Waltham, MA · filing with the SEC since 2020
Who owns Damora Therapeutics, Inc.
As filed with the SECHolders of 5% or more
6
Fairmount Funds Management LLC holds 20% of Common Stock, par value $0.00001 per share, as its SCHEDULE 13D/A filed Feb 11, 2026 says.
Directors and officers
16
report now, of 35 people on the record since 2020. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 6 named at left.
Holders of 5% or moreshare of the class, as filed
Fairmount Funds Management LLC
SCHEDULE 13D/A · filed Feb 11, 2026 · Common Stock, par value $0.00001 per share · 20% in Nov 17, 2025
Fmr LLC
SCHEDULE 13G · filed Dec 5, 2025 · COMMON STOCK
Otto Erik
SCHEDULE 13G/A · filed Feb 9, 2024 · Common Stock
Avoro Capital Advisors LLC
SCHEDULE 13G · filed May 15, 2026 · Common Stock, par value $0.00001 per share
Venrock Healthcare Capital Partners III, L.P.
SCHEDULE 13G · filed Feb 17, 2026 · Common Stock, $0.00001 par value per share
Blackrock, Inc.
SCHEDULE 13G · filed Jul 28, 2026 · Common Stock
Paramora Holding LLC
SCHEDULE 13G/A · filed Apr 23, 2026 · Common Stock, par value $0.00001 per share · reported falling below 5%, from 7.5% in Jan 12, 2026
Paragon Therapeutics, Inc.
SCHEDULE 13G/A · filed Apr 23, 2026 · Common Stock, par value $0.00001 per share · reported falling below 5%, from 7.5% in Jan 12, 2026
Point72 Asset Management, L.P.
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, par value $0.00001 per share · reported falling below 5%, from 6.3% in Nov 13, 2025
Ikarian Capital, LLC
SCHEDULE 13G/A · filed Mar 6, 2026 · Common Stock, $0.00001 par value per share · reported falling below 5%, from 21.5% in Dec 5, 2025
Jain Global LLC
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, $0.00001 par value per share · reported falling below 5%, from 7.5% in Feb 17, 2026
Novo Holdings A/S
SCHEDULE 13D/A · filed Oct 9, 2025 · Common Stock, par value $0.00001 per share · reported falling below 5%, from 6.5% in Sep 25, 2025
What DMRA reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Damora Therapeutics
A company bought · asset acquisition · Oct 2025 · owns, named in the 10-K filed Mar 19, 2026
Damora Therapeutics LLC
A company bought · asset acquisition · owns, named in the 10-K filed Mar 19, 2026
Damora Therapeutics, Inc.
A company bought · asset acquisition · owns, named in the 10-K filed Mar 19, 2026
5 subsidiaries in 3 countries, from the list filed with the 10-K filed Mar 19, 2026.
Insider tradesForm 4
4sales
1purchases
0sales on a scheduled plan
3people selling
$0sold, in dollars
$300,000bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window4 of 37 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Jarrett Jennifer | Director, President and CEO | 0 | $0 | 0 | 1 | $300,000 |
| Schambye Hans T. | Chief Executive Officer | 1 | $0 | 0 | 0 | $0 |
| Firmani Lori | Chief Financial Officer | 1 | $0 | 0 | 0 | $0 |
| Winslow Garrett | General Counsel | 2 | $0 | 0 | 0 | $0 |